vs
EGAIN Corp（EGAN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是EGAIN Corp的1.3倍（$30.3M vs $23.0M），EGAIN Corp净利率更高（10.2% vs -221.3%，领先231.5%），REGENXBIO Inc.同比增速更快（43.0% vs 2.6%），EGAIN Corp自由现金流更多（$9.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 1.4%）
eGain公司总部位于加利福尼亚州桑尼维尔，主营人工智能知识软件开发，助力企业实现客户体验与员工工作流程的智能化自动化升级，帮助企业提升运营效率，优化服务质量。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EGAN vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.0M
营收增速更快
RGNX
高出40.4%
2.6%
净利率更高
EGAN
高出231.5%
-221.3%
自由现金流更多
EGAN
多$62.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
1.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $30.3M |
| 净利润 | $2.3M | $-67.1M |
| 毛利率 | 73.1% | — |
| 营业利润率 | 8.9% | -190.0% |
| 净利率 | 10.2% | -221.3% |
| 营收同比 | 2.6% | 43.0% |
| 净利润同比 | 248.1% | -31.2% |
| 每股收益（稀释后） | $0.08 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGANRGNX
| Q4 25 | $23.0M | $30.3M | ||
| Q3 25 | $23.5M | $29.7M | ||
| Q2 25 | $23.2M | $21.4M | ||
| Q1 25 | $21.0M | $89.0M | ||
| Q4 24 | $22.4M | $21.2M | ||
| Q3 24 | $21.8M | $24.2M | ||
| Q2 24 | $22.5M | $22.3M | ||
| Q1 24 | $22.4M | $15.6M |
净利润EGANRGNX
| Q4 25 | $2.3M | $-67.1M | ||
| Q3 25 | $2.8M | $-61.9M | ||
| Q2 25 | $30.9M | $-70.9M | ||
| Q1 25 | $66.0K | $6.1M | ||
| Q4 24 | $671.0K | $-51.2M | ||
| Q3 24 | $652.0K | $-59.6M | ||
| Q2 24 | $1.5M | $-53.0M | ||
| Q1 24 | $1.5M | $-63.3M |
毛利率EGANRGNX
| Q4 25 | 73.1% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 72.7% | — | ||
| Q1 25 | 68.0% | — | ||
| Q4 24 | 70.2% | 70.2% | ||
| Q3 24 | 69.4% | 48.8% | ||
| Q2 24 | 69.3% | 52.5% | ||
| Q1 24 | 69.3% | 72.6% |
营业利润率EGANRGNX
| Q4 25 | 8.9% | -190.0% | ||
| Q3 25 | 12.1% | -176.3% | ||
| Q2 25 | 14.0% | -296.3% | ||
| Q1 25 | 0.1% | 13.6% | ||
| Q4 24 | 2.9% | -242.1% | ||
| Q3 24 | 2.3% | -256.6% | ||
| Q2 24 | 5.3% | -251.3% | ||
| Q1 24 | 4.2% | -408.8% |
净利率EGANRGNX
| Q4 25 | 10.2% | -221.3% | ||
| Q3 25 | 12.0% | -208.3% | ||
| Q2 25 | 132.8% | -331.8% | ||
| Q1 25 | 0.3% | 6.8% | ||
| Q4 24 | 3.0% | -241.3% | ||
| Q3 24 | 3.0% | -246.3% | ||
| Q2 24 | 6.7% | -237.7% | ||
| Q1 24 | 6.7% | -405.4% |
每股收益（稀释后）EGANRGNX
| Q4 25 | $0.08 | $-1.30 | ||
| Q3 25 | $0.10 | $-1.20 | ||
| Q2 25 | $1.09 | $-1.38 | ||
| Q1 25 | $0.00 | $0.12 | ||
| Q4 24 | $0.02 | $-0.99 | ||
| Q3 24 | $0.02 | $-1.17 | ||
| Q2 24 | $0.05 | $-1.05 | ||
| Q1 24 | $0.05 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $88.8M | $102.7M |
| 总资产 | $146.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EGANRGNX
| Q4 25 | $83.1M | $230.1M | ||
| Q3 25 | $70.9M | $274.2M | ||
| Q2 25 | $62.9M | $323.3M | ||
| Q1 25 | $68.7M | $267.9M | ||
| Q4 24 | $70.5M | $234.7M | ||
| Q3 24 | $67.2M | $255.5M | ||
| Q2 24 | $70.0M | $290.4M | ||
| Q1 24 | $83.0M | $338.7M |
股东权益EGANRGNX
| Q4 25 | $88.8M | $102.7M | ||
| Q3 25 | $83.5M | $161.5M | ||
| Q2 25 | $80.7M | $213.7M | ||
| Q1 25 | $51.6M | $274.2M | ||
| Q4 24 | $55.3M | $259.7M | ||
| Q3 24 | $55.7M | $301.4M | ||
| Q2 24 | $58.5M | $348.3M | ||
| Q1 24 | $63.9M | $390.7M |
总资产EGANRGNX
| Q4 25 | $146.8M | $453.0M | ||
| Q3 25 | $144.6M | $525.2M | ||
| Q2 25 | $148.0M | $581.0M | ||
| Q1 25 | $106.2M | $490.9M | ||
| Q4 24 | $111.3M | $466.0M | ||
| Q3 24 | $114.9M | $519.1M | ||
| Q2 24 | $127.9M | $569.4M | ||
| Q1 24 | $120.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $9.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 43.0% | -174.0% |
| 资本支出强度资本支出/营收 | 1.0% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.33× | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EGANRGNX
| Q4 25 | $10.1M | $-52.3M | ||
| Q3 25 | $10.4M | $-56.0M | ||
| Q2 25 | $-4.3M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $6.4M | $-31.6M | ||
| Q3 24 | $954.0K | $-40.5M | ||
| Q2 24 | $-5.1M | $-45.5M | ||
| Q1 24 | $1.7M | $-55.5M |
自由现金流EGANRGNX
| Q4 25 | $9.9M | $-52.8M | ||
| Q3 25 | $10.2M | $-56.5M | ||
| Q2 25 | $-4.5M | $-49.7M | ||
| Q1 25 | $2.1M | $32.6M | ||
| Q4 24 | $6.3M | $-32.7M | ||
| Q3 24 | $845.0K | $-40.9M | ||
| Q2 24 | $-5.2M | $-46.0M | ||
| Q1 24 | $1.7M | $-56.0M |
自由现金流率EGANRGNX
| Q4 25 | 43.0% | -174.0% | ||
| Q3 25 | 43.4% | -189.9% | ||
| Q2 25 | -19.5% | -232.8% | ||
| Q1 25 | 10.0% | 36.6% | ||
| Q4 24 | 28.1% | -154.2% | ||
| Q3 24 | 3.9% | -168.9% | ||
| Q2 24 | -23.0% | -206.2% | ||
| Q1 24 | 7.8% | -358.5% |
资本支出强度EGANRGNX
| Q4 25 | 1.0% | 1.7% | ||
| Q3 25 | 1.0% | 1.7% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 0.5% | 1.2% | ||
| Q4 24 | 0.6% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率EGANRGNX
| Q4 25 | 4.33× | — | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | 5.53× | ||
| Q4 24 | 9.57× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | — | ||
| Q1 24 | 1.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
